Using Pharmacogenetics to Find Treatment for Familial Hypercholesterolemia Patients with Both apoB and PCSK9 Mutations
Familial hypercholesterolemias (FH) are inherited mutations that cause elevated total cholesterol and low-density lipoprotein cholesterol levels (LDL-C) which lead to premature coronary heart diseases. Pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which ca...
Main Author: | Cho, Elizabeth |
---|---|
Format: | Others |
Published: |
Scholarship @ Claremont
2019
|
Subjects: | |
Online Access: | https://scholarship.claremont.edu/scripps_theses/1229 https://scholarship.claremont.edu/cgi/viewcontent.cgi?article=2377&context=scripps_theses |
Similar Items
-
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
by: Jean-Philippe Drouin-Chartier, et al.
Published: (2017-06-01) -
EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01) -
High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent
by: A.C. Rodrigues, et al.
Published: (2005-09-01) -
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia
by: Li Ma, et al.
Published: (2012-11-01) -
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
by: Khalid Al-Waili, et al.
Published: (2013-01-01)